MADRIGAL PHARMACEUTICALS, INC.
Last · NASDAQ$460.01+7.89 (+1.75%)close · yahoo · 16h ago
Market cap$10.63B23.1M sh
P/E · TTM-35.8fwd 47.8 · eps -12.85 · loss
Beta-1.05vs S&P 500
Div yield0.00%annual · TTM
52w range
$393.61$615.00
Volume326.9Ksession
| Revenue | $675.6M |
|---|---|
| Operating income | $-149.0M |
| Net income | $-152.3M |
| Free cash flow | $-152.2M |
| Operating margin | -22.1% |
| Net margin | -22.5% |
| Return on equity | -29.1% |
| Period | 2026 |
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.09
Est. revenue
406.3M
Press & signals
- GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags